GILD vs VRTX
GILD and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $180.62B | $137.30B |
| P/E (TTM) | 21.5 | 31.6 |
| P/B | 15.27 | 6.78 |
| P/S | 6.1x | 11.4x |
| Dividend yield | 2.22% | — |
| Revenue | $30.46B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 2.4% | 8.9% |
| Net income | -$3.24B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 1672.9% | 838.1% |
| EPS, diluted | $-2.65(TTM) | $17.17(TTM) |
| EBIT margin | 34.0% | 34.8% |
| ROE | 71.9% | 19.5% |
| ROIC | 26.7% | 25.0% |
| 1y total return | +32.3% | +38.1% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: GILD frente a VRTX
| Métrica | GILD | VRTX |
|---|---|---|
| Valor final | $20.7K | $64.1K |
| Retorno total | +107.3% | +541.0% |
| CAGR | +7.3% | +19.7% |
| Volatilidad | 25.8% | 32.9% |
| Sharpe | 0.25 | 0.59 |
| Sortino | 0.37 | 0.88 |
| Caída máxima | -35.0% | -41.6% |
Basado en 2600 días de negociación comunes, 2016-04-27 → 2026-08-28 · tasa libre de riesgo 3.9% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)